dr. dowdy on the association of molecular subtypes and responses to bevacizumab in ovarian cancer
Published 9 years ago • 228 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
1:05
dr. dowdy on bevacizumab and improvement of pfs in ovarian cancer
-
1:59
ovarian cancer subtypes may predict response to bevacizumab
-
1:35
dr. landen on molecular subtypes of ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
1:40
dr. burger on the toxicity profile of bevacizumab in ovarian cancer
-
7:24
ovarian cancer: maintenance following frontline bevacizumab
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
8:15
bevacizumab in ovarian cancer
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
0:58
dr. cohen on the evolution of surgery in ovarian cancer
-
1:45
dr. liu on the use of bevacizumab in newly diagnosed advanced ovarian cancer
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
1:06
dr. jason konner discusses bevacizumab in ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
2:01
dr. du bois on study of secondary cytoreductive surgery in ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
4:54
bevacizumab in recurrent ovarian cancer
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer